AT
ATOS.US Atossa Genetics Inc
- Market cap
- USD 19.6M
- P/E
- -
- P/B
- 0.89x
- ROE
- -145.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ATOS.US undervalued?
Graham numberThe Graham number of Atossa Genetics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Atossa Genetics Inc fundamental analysis
No fundamental analysis for Atossa Genetics Inc yet.
Atossa Genetics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Atossa Genetics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Gene…
Full company profileAtossa Genetics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Atossa Genetics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -303K | -129K | -44.2K | -52.8K | -46.6K | -23.0K | -8.00K | -23.0K | -17.0K | -16.0K | - |
| Operating Income | -7.25M | -7.19M | -11.4M | -17.3M | -14.6M | -20.5M | -27.7M | -31.4M | -27.6M | -37.1M | -32.6M |
| EBITDA | -6.07M | -7.80M | -11.4M | -17.2M | -14.6M | -20.6M | -27.7M | -30.1M | -25.5M | -34.8M | -32.0M |
| Net Income | -6.37M | -8.12M | -11.4M | -17.2M | -17.8M | -20.6M | -26.2M | -30.1M | -25.5M | -34.8M | -31.6M |
| EPS | -389 | -125 | -41 | -30 | -24 | -2.64 | -3.11 | -3.58 | -3.04 | -4.04 | -3.17 |
| Balance Sheet | |||||||||||
| Total Assets | 4.14M | 8.16M | 11.7M | 14.5M | 42.8M | 141M | 124M | 96.3M | 76.4M | 47.6M | 26.4M |
| Total Liabilities | 1.05M | 1.23M | 2.92M | 1.34M | 15.7M | 3.13M | 5.57M | 5.24M | 4.97M | 8.26M | 4.71M |
| Shareholders' Equity | 3.10M | 6.94M | 8.81M | 13.2M | 27.2M | 138M | 118M | 91.0M | 71.5M | 39.4M | 21.7M |
| Cash & Short-term Investments | 3.03M | 7.22M | 10.4M | 12.7M | 39.7M | 136M | 111M | 88.5M | 71.1M | 41.3M | 20.6M |
| Total Debt | - | - | - | 50.5K | 18.1K | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.37M | -6.59M | -8.96M | -9.13M | -11.6M | -16.5M | -20.8M | -20.9M | -21.0M | -29.8M | -33.0M |
| Capital Expenditure | 9.21K | 111K | 111K | 7.63K | 9.37K | 9.00K | 27.0K | 14.0K | 19.0K | 23.0K | 0.00 |
| Free Cash Flow | -5.38M | -6.59M | -9.07M | -9.14M | -11.6M | -16.5M | -20.8M | -21.0M | -21.0M | -29.8M | -33.0M |
| Ratios | |||||||||||
| ROE | -205.6% | -117.1% | -129.5% | -131.0% | -65.6% | -14.9% | -22.2% | -33.1% | -35.7% | -88.4% | -145.5% |
| ROA | -153.7% | -99.5% | -97.3% | -118.9% | -41.6% | -14.6% | -21.2% | -31.3% | -33.4% | -73.0% | -119.6% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Atossa Genetics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 4.50M | 5.97 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Feb 2, 2026.
Who owns Atossa Genetics Inc
- Insiders 1.85%
- Institutions 12.29%
- Public & others 85.86%
- Shares outstanding 9.98M
- Free float 9.94M
Top funds holding ATOS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 256K | 2.57% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 44.6K | 0.45% | -0.38% | Sep 2026 |
| Abante Quant Value FI | 40.2K | 0.40% | 0.00% | Aug 2026 |
| Columbia Small Cap Value Discv A | 19.1K | 0.19% | -90.12% | Sep 2026 |
| Fidelity Total Market Index | 14.4K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 12.6K | 0.13% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 6.54K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 4.91K | 0.05% | 0.00% | Aug 2026 |
| Columbia VP Small Cap Value Discovery 1 | 3.34K | 0.03% | -90.12% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 3.09K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.99K | 0.02% | 0.00% | Sep 2026 |
| BlackRock Diversified Equity Alpha Inst | 952.00 | 0.01% | 0.00% | Jul 2026 |
Top institutions holding ATOS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 362K | 3.63% | +3.62% | Jun 2026 |
| Ameriprise Financial Inc | 258K | 2.59% | +1.22% | Jun 2026 |
| BlackRock Inc | 164K | 1.65% | +23.42% | Jun 2026 |
| Renaissance Technologies Corp | 132K | 1.32% | +21.13% | Jun 2026 |
| Geode Capital Management, LLC | 92.4K | 0.93% | -4.82% | Jun 2026 |
| UBS Group AG | 82.6K | 0.83% | -10.23% | Jun 2026 |
| Jane Street Group LLC | 56.6K | 0.57% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 52.6K | 0.53% | +0.67% | Jun 2026 |
| Millennium Management LLC | 46.5K | 0.47% | -30.31% | Jun 2026 |
| State Street Corp | 39.8K | 0.40% | 0.00% | Jun 2026 |
| Northern Trust Corp | 20.2K | 0.20% | +5.33% | Jun 2026 |
| Susquehanna International Group, LLP | 15.6K | 0.16% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 12.3K | 0.12% | -23.81% | Jun 2026 |
| Vanguard Global Advisers, LLC | 3.09K | 0.03% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 2.06K | 0.02% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 1.99K | 0.02% | +209.63% | Jun 2026 |
| Mcf Advisors, LLC | 1.07K | 0.01% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 666.00 | 0.01% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 587.00 | 0.01% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 390.00 | 0.00% | +1.83% | Jun 2026 |
Atossa Genetics Inc company profile
- Company name
- Atossa Genetics Inc
- Ticker
- ATOS.US
- Exchange
- USA Stocks
- Listed since
- Nov 8, 2012
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 16
- Fiscal year end
- December
- Address
- 448 NW Market Street, Seattle, WA, United States, 98107
- Phone
- 206 588 0256
- Website
- atossatherapeutics.com
About Atossa Genetics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Atossa Genetics Inc management
5- Dr. Steven C. Quay FCAP, M.D., Ph.D.Chairman, CEO & President · born 1951
- Mr. Mark J. Daniel CPAChief Financial Officer · born 1977
- Ms. Janet Rose Rea MSPH, RACSenior Vice President of Research & Development
- Ms. Delly Behen P.H.R.Senior Vice President of Business Operations
- Dr. Richard Graydon M.D., Ph.D.Interim Chief Medical Officer